Getting Started: Understanding PASH Syndrome
At a Glance
PASH syndrome is a rare condition in which an overactive immune system causes pyoderma gangrenosum, severe acne, and hidradenitis suppurativa. It is not contagious or caused by poor hygiene; care focuses on reducing inflammation and treating infections that develop.
If you have spent years visiting different doctors for painful skin lumps, severe acne, and deep ulcers—only to be told you have a “stubborn infection” or that you simply need better hygiene—you are not alone. Receiving a diagnosis of PASH Syndrome can be overwhelming, but it is often the first step toward a treatment plan that actually addresses what is happening inside your body [1][2].
PASH is an acronym for three conditions that occur together:
- Pyoderma gangrenosum (painful, rapidly enlarging skin ulcers).
- Acne (typically severe nodulocystic or acne conglobata).
- Suppurative Hidradenitis (painful nodules, abscesses, and scarring in areas like the armpits or groin) [3].
Understanding the Rarity
PASH is exceptionally rare. While the exact number of people living with it globally is unknown, medical literature consists mostly of small groups of patients or individual case reports [1][4]. Because it is so uncommon, many healthcare providers have never seen a case, which often leads to a long and frustrating diagnostic journey [4]. Most patients find that their symptoms begin in adolescence or young adulthood, often starting with acne or hidradenitis suppurativa (HS) before the more severe ulcers of pyoderma gangrenosum (PG) appear later [3].
This Is Not a Primary Infection
One of the most important things to understand about PASH is its cause. It is thought to be an autoinflammatory disease, rather than primarily an infection [5].
- Autoinflammatory means your innate immune system (the part of your immune system that provides immediate defense) is dysregulated and attacks your own healthy tissues [6].
- It is different from an autoimmune disease, where the body creates specific antibodies against itself.
- Because the inflammation comes from within, PASH cannot be “caught” from someone else, and it is not caused by a lack of cleanliness [6][7].
While the initial cause of the skin lesions is immune-driven, they can sometimes look exactly like an infection. Furthermore, these open wounds and tunnels are frequently colonized by or secondarily infected with bacteria [3]. This is why standard antibiotics alone often fail to clear the skin entirely, though they are sometimes used for their anti-inflammatory properties or to treat documented secondary infections [1].
The Role of Genetics
PASH is considered a polygenic condition [4][6]. This means it is likely associated with small variations in multiple genes rather than a single “broken” gene that can be easily tested for in every patient [8].
Researchers have found variants in several genes related to inflammation—such as MEFV, NLRP3, and PSTPIP1—in some people with PASH, but no two patients are exactly alike, and these are not routine diagnostic markers [5][6]. Unlike related syndromes that cause joint inflammation (like PAPA syndrome), PASH does not have a single “smoking gun” genetic marker that confirms the diagnosis [8]. Instead, doctors diagnose it by confirming your clinical symptoms: the combination of PG, acne, and HS [3].
Living with the Burden of PASH
The physical and emotional toll of PASH can be significant. The three main symptoms create a cycle of pain and healing that can feel constant:
- Painful Ulcers: The ulcers of pyoderma gangrenosum can be intensely painful and expand quickly, making movement difficult depending on their location [9][10].
- Drainage and Odor: The abscesses and tunnels (sinus tracts) from HS can produce malodorous drainage, which many patients find distressing or embarrassing [2][11].
- Scarring: Both HS and PG can lead to significant scarring. HS often leaves bridge-like scars or deep tunnels under the skin, while PG can leave “cribriform” (cigarette-paper-like) scars after an ulcer heals [12][13].
Because these symptoms are visible and painful, they often impact quality of life, leading to high rates of anxiety and depression [11][14]. Recognizing that these feelings are a logical response to a severe, chronic condition is a vital part of your care. Modern treatments, including biologics (targeted immune-system medications used off-label), are increasingly being used to manage the underlying inflammation, which can help heal ulcers and reduce the frequency of new flares [1][5].
Your diagnosis is not a reflection of anything you did wrong; it is a complex biological puzzle that requires a specialized, compassionate care team to manage [2][1].
Common questions in this guide
What is PASH syndrome, and which conditions does it include?
Is PASH syndrome an infection or something I can spread?
How do doctors diagnose PASH syndrome?
Does PASH syndrome have a known genetic cause?
What treatments can help PASH syndrome?
Can PASH syndrome cause scarring and affect mental health?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Have you confirmed all three components of PASH—pyoderma gangrenosum, acne, and hidradenitis suppurativa—in my case?
- 2.What specific tests or biopsies were used to evaluate for infection before we started my current treatment?
- 3.Since PASH is autoinflammatory, should I be screened for other related conditions like inflammatory bowel disease (IBD) or arthritis if I develop symptoms?
- 4.Do you recommend genetic testing for me, and if so, how will the results change my treatment plan?
- 5.What is the long-term plan for managing my pain and preventing further scarring or mobility issues?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) syndrome: a single-institution case series with a focus on management.
Yan A, Gallardo M, Savu A, Kaffenberger B
Archives of dermatological research 2024; (316(7)):397 doi:10.1007/s00403-024-03125-7.
PMID: 38878169 - 2
Rapid Remission through Multimodal Therapy in a Severe Form of PASH Syndrome: A Case Report.
Lohmer CB, von Stebut-Marx J, Wilhelm T, et al.
Case reports in dermatology 2026; (18(1)):256-263 doi:10.1159/000551256.
PMID: 42256375 - 3
Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa Syndrome: A Case Report and Literature Review.
Huang J, Tsang LS, Shi W, Li J
Frontiers in medicine 2022; (9()):856786 doi:10.3389/fmed.2022.856786.
PMID: 35402426 - 4
Altered keratinization and vitamin D metabolism may be key pathogenetic pathways in syndromic hidradenitis suppurativa: a novel whole exome sequencing approach.
Brandao L, Moura R, Tricarico PM, et al.
Journal of dermatological science 2020; (99(1)):17-22 doi:10.1016/j.jdermsci.2020.05.004.
PMID: 32518053 - 5
Autoinflammatory Syndromes of Hidradenitis Suppurativa: Updates in Clinical Features, Emerging Associations, and Management.
Ho JY, Liang AL, Maronese CA, et al.
Current rheumatology reports 2026; (28(1)).
PMID: 42593626 - 6
Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis).
Marzano AV, Damiani G, Ceccherini I, et al.
The British journal of dermatology 2017; (176(6)):1588-1598 doi:10.1111/bjd.15226.
PMID: 27943240 - 7
Neutrophilic dermatoses.
Delaleu J, Lepelletier C, Calugareanu A, et al.
La Revue de medecine interne 2022; (43(12)):727-738 doi:10.1016/j.revmed.2022.06.007.
PMID: 35870984 - 8
PAPA spectrum disorders.
Genovese G, Moltrasio C, Garcovich S, Marzano AV
Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2020; (155(5)):542-550 doi:10.23736/S0392-0488.20.06629-8.
PMID: 32618443 - 9
The Clinical and Molecular Response of Pyoderma Gangrenosum to IL-23 Blockade: Result from a Proof-of-Concept Open-Label Clinical Trial.
Flora A, Pham J, Woods JA, et al.
The Journal of investigative dermatology 2025; (145(6)):1396-1406.e6 doi:10.1016/j.jid.2024.10.602.
PMID: 39547392 - 10
Updates in innovation of the treatment of pyoderma gangrenosum.
Keum H, Zhivov EV, Ortega-Loayza AG
Expert review of clinical pharmacology 2025; (18(1-2)):29-39 doi:10.1080/17512433.2024.2447776.
PMID: 39720859 - 11
The epidemiology of hidradenitis suppurativa.
Ingram JR
The British journal of dermatology 2020; (183(6)):990-998 doi:10.1111/bjd.19435.
PMID: 32880911 - 12
Hidradenitis Suppurativa in a Patient with Smith-Magenis Syndrome: A Case Report.
McKenzie SA, Ni CS, Hsiao JL
Cureus 2019; (11(6)):e4970 doi:10.7759/cureus.4970.
PMID: 31453042 - 13
Recalcitrant Ulcerative Pyoderma Gangrenosum of the Leg Responsive to Tildrakizumab: A Case Report.
Leow LJ, Zubrzycki N
Clinical, cosmetic and investigational dermatology 2022; (15()):1729-1736 doi:10.2147/CCID.S374534.
PMID: 36039180 - 14
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.
Garg A, Malviya N, Strunk A, et al.
Journal of the American Academy of Dermatology 2022; (86(5)):1092-1101 doi:10.1016/j.jaad.2021.01.059.
PMID: 33493574
This page explains PASH syndrome for educational purposes and does not replace medical advice. A dermatologist or other qualified clinician can help confirm the diagnosis, assess possible secondary infection, and tailor treatment to your symptoms.
Get notified when new evidence is published on PASH syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.